Sorafenib for advanced hepatocellular carcinoma (HCC): Impact of rationing in the United Kingdom

被引：1
|
作者：
Palmer, D. H. [1 ]
Hussain, S. A. [1 ]
Smith, A. J. [1 ]
Hull, D. [1 ]
Johnson, P. J. [1 ]
机构：
[1] Canc Res UK Inst Canc Studies, Birmingham, W Midlands, England
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.e14516
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e14516
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Early experience of combination treatment of sorafenib and radiotherapy in patients with advanced hepatocellular carcinoma (HCC)
    Seong, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [22] Phase I study of everolimus in combination with sorafenib in patients with advanced hepatocellular carcinoma (HCC).
    Finn, R. S.
    Poon, R. T. P.
    Yau, T.
    Klumpen, H.
    Chen, L.
    Kang, Y.
    Kim, T.
    Gomez-Martin, C.
    Rodriguez-Lope, C.
    Kunz, T.
    Paquet, T.
    Asubonteng, K.
    Winkler, R. E.
    Anak, O.
    Sellami, D. B.
    Bruix, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [23] Influence of underlying liver disease on response to sorafenib in patients with advanced hepatocellular carcinoma (HCC)
    Bouattour, M.
    Faivre, S. J.
    Dreyer, C.
    Paradis, V.
    Raymond, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [24] Hepatocellular carcinoma (HCC): beyond sorafenib-chemotherapy
    Kim, Dae Won
    Talati, Chetasi
    Kim, Richard
    JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (02) : 256 - 265
  • [25] Oral sorafenib for advanced hepatocellular carcinoma
    Nature Clinical Practice Oncology, 2006, 3 (12): : 648 - 649
  • [26] Sorafenib for the treatment of advanced hepatocellular carcinoma
    Connock, M.
    Round, J.
    Bayliss, S.
    Tubeuf, S.
    Greenheld, W.
    Moore, D.
    HEALTH TECHNOLOGY ASSESSMENT, 2010, 14 : 17 - 21
  • [27] Sorafenib Effectiveness in Advanced Hepatocellular Carcinoma
    Sanoff, Hanna K.
    Chang, YunKyung
    Lund, Jennifer L.
    O'Neil, Bert H.
    Dusetzina, Stacie B.
    ONCOLOGIST, 2016, 21 (09) : 1113 - 1120
  • [28] A phase I trial of the combination of temsirolimus (TEM) and sorafenib (SOR) in advanced hepatocellular carcinoma (HCC)
    Kelley, R. K.
    Nimeiri, H. S.
    Vargo, M. T.
    Bergsland, E. K.
    Ko, A. H.
    Munster, P. N.
    Reinert, A.
    Mulcahy, M. F.
    Benson, A. B.
    Venook, A. P.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [29] Sorafenib in Advanced Hepatocellular Carcinoma Reply
    Llovet, Josep M.
    Bruix, Jordi
    NEW ENGLAND JOURNAL OF MEDICINE, 2008, 359 (23) : 2498 - 2499
  • [30] BENEFIT OF SORAFENIB ACCORDING TO UNDERLYING LIVER DISEASE ETIOLOGY IN PATIENTS WITH ADVANCED HEPATOCELLULAR CARCINOMA (HCC)
    Bouattour, M.
    Goutte, N.
    Vullierme, M. -P.
    Castelnau, C.
    Farges, O.
    Faivre, S.
    Durand, F.
    Castera, L.
    JOURNAL OF HEPATOLOGY, 2014, 60 (01) : S407 - S407
12345